LOS ANGELES--(BUSINESS WIRE)--Goldberg Law PC (http://www.Goldberglawpc.com) announces that it is investigating claims of potential misrepresentations by Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.
If you purchased or otherwise acquired Revance shares and would like more information regarding the investigation, we advise you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 13650 Marina Pointe Dr. Suite 1404, Marina Del Rey, CA 90292, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at firstname.lastname@example.org.
The investigation concerns whether the Company violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Specifically, the investigation will focus on the allegedly misleading statements found in the Company’s public announcements and SEC filings which failed to disclose, among other things, that: (i) Revance had not commenced a Phase 3 clinical trial of RT001—its lead product under development for the treatment of wrinkles around the eyes—in the first quarter of 2014; and (ii) Revance did not have the quality or quantity of RT001 on hand sufficient to complete and successful Phase 3 clinical trial.
If you have any questions concerning your legal rights in this case, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at email@example.com.
Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.